Eastern Asia: Market for Other Medicaments For Therapeutic Or Prophylactic Uses 2024

Market Size for Other Medicaments For Therapeutic Or Prophylactic Uses in Eastern Asia

The East Asian market for other medicaments for therapeutic or prophylactic uses stood at $X in 2022, surging by X% against the previous year. Over the period under review, consumption, however, posted a strong increase. Over the period under review, the market reached the maximum level in 2022 and is likely to see gradual growth in the immediate term.

Production of Other Medicaments For Therapeutic Or Prophylactic Uses in Eastern Asia

In value terms, production of other medicaments for therapeutic or prophylactic uses stood at $X in 2022 estimated in export price. Overall, production, however, showed a resilient expansion. The pace of growth was the most pronounced in 2019 when the production volume increased by X%. The level of production peaked at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Other Medicaments For Therapeutic Or Prophylactic Uses

Exports in Eastern Asia

Exports of other medicaments for therapeutic or prophylactic uses skyrocketed to X tons in 2022, rising by X% against the year before. Overall, exports, however, showed a relatively flat trend pattern. The most prominent rate of growth was recorded in 2020 with an increase of X%. As a result, the exports reached the peak of X tons. From 2021 to 2022, the growth of the exports of remained at a lower figure.

In value terms, exports of other medicaments for therapeutic or prophylactic uses surged to $X in 2022. In general, exports, however, showed a mild decrease. Over the period under review, the exports of attained the maximum at $X in 2012; however, from 2013 to 2022, the exports failed to regain momentum.

Exports by Country

China prevails in uses structure, amounting to X tons, which was near X% of total exports in 2022. The following exporters - Taiwan (Chinese) (X tons) and South Korea (X tons) - each resulted at a X% share of total exports.

China was also the fastest-growing in terms of the other medicaments for therapeutic or prophylactic uses exports, with a CAGR of X% from 2012 to 2022. At the same time, South Korea (X%) displayed positive paces of growth. By contrast, Taiwan (Chinese) (X%) illustrated a downward trend over the same period. China (X p.p.) significantly strengthened its position in terms of the total exports, while Taiwan (Chinese) saw its share reduced by X% from 2012 to 2022, respectively. The shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, China ($X) remains the largest other medicaments for therapeutic or prophylactic uses supplier in Eastern Asia, comprising X% of total exports. The second position in the ranking was taken by South Korea ($X), with an X% share of total exports.

From 2012 to 2022, the average annual rate of growth in terms of value in China stood at X%. The remaining exporting countries recorded the following average annual rates of exports growth: South Korea (X% per year) and Taiwan (Chinese) (X% per year).

Export Prices by Country

In 2022, the export price in Eastern Asia amounted to $X per ton, with a decrease of X% against the previous year. In general, the export price continues to indicate a mild setback. The pace of growth appeared the most rapid in 2021 when the export price increased by X%. The level of export peaked at $X per ton in 2012; however, from 2013 to 2022, the export prices remained at a lower figure.

There were significant differences in the average prices amongst the major exporting countries. In 2022, amid the top suppliers, the country with the highest price was South Korea ($X per ton), while Taiwan (Chinese) ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by China (X%), while the other leaders experienced mixed trends in the export price figures.

Imports of Other Medicaments For Therapeutic Or Prophylactic Uses

Imports in Eastern Asia

For the fourth consecutive year, Eastern Asia recorded growth in purchases abroad of other medicaments for therapeutic or prophylactic uses, which increased by X% to X tons in 2022. Overall, imports, however, continue to indicate a noticeable contraction. The volume of import peaked at X tons in 2012; however, from 2013 to 2022, imports remained at a lower figure.

In value terms, imports of other medicaments for therapeutic or prophylactic uses totaled $X in 2022. Total imports indicated a pronounced expansion from 2012 to 2022: its value increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, imports increased by X% against 2018 indices. The most prominent rate of growth was recorded in 2021 when imports increased by X%. The level of import peaked in 2022 and is likely to see steady growth in the near future.

Imports by Country

In 2022, China (X tons) and South Korea (X tons) were the major importers of other medicaments for therapeutic or prophylactic uses in Eastern Asia, together constituting X% of total imports. Japan (X tons) held a X% share (based on physical terms) of total imports, which put it in second place, followed by Hong Kong SAR (X%) and Taiwan (Chinese) (X%).

From 2012 to 2022, the biggest increases were recorded for China (with a CAGR of X%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, China ($X), Japan ($X) and South Korea ($X) were the countries with the highest levels of imports in 2022, with a combined X% share of total imports.

China, with a CAGR of X%, saw the highest rates of growth with regard to the value of imports, in terms of the main importing countries over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

In 2022, the import price in Eastern Asia amounted to $X per ton, which is down by X% against the previous year. Import price indicated a resilient increase from 2012 to 2022: its price increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, import price for other medicaments for therapeutic or prophylactic uses decreased by X% against 2018 indices. The most prominent rate of growth was recorded in 2013 an increase of X% against the previous year. Over the period under review, import prices hit record highs at $X per ton in 2018; however, from 2019 to 2022, import prices remained at a lower figure.

There were significant differences in the average prices amongst the major importing countries. In 2022, amid the top importers, the country with the highest price was Japan ($X per ton), while South Korea ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Taiwan (Chinese) (X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :